Articles On Race Oncology (ASX:RAC)

Digital healthcare service has evolved as one of the fastest-growing industries in the modern era. Introduction of technology in medical science has emerged as one of the biggest blessings for human. Digitally connected network systems have...

The funding will be used to advance clinical projects for Race’s cancer drug Bisantrene.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Race Oncology (ASX:RAC) has announced the successful completion of a $1.45 million placement, led by biotechnology investor Dr Daniel Tillett.

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

On Stockhead today, investors should fall back in love with junior explorers once tech and cannabis lose their appeal, Opthea may need a bit of cash but it’s recent success has put it in a strong position, and Antler has invested $1.2m in p...

A one-day gain of 148 per cent has Opthea as comfortably the best-performing small cap health or biotech stock on the ASX at a time when the majority are trending downwards. Stockhead reported today on Opthea’s (ASX:OPT) positive results fr...

Rare cancers can hurt every bit as much as more common cancers, but as it happens, they’re often too rare to present a target market for big pharmaceuticals. One of these rare cancers is myelogenous leukemia and a drug being put to the test...

The pharmaceutical market in Australia is defined as a knowledge-intensive, technology-driven industry that is well poised to contribute to the overall economic activity and particularly enhance social wellbeing. The S&P/ASX 200 Health...

Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

“This is a major milestone for Race, because it’s the first treatment with Bisantrene since the drug disappeared more than 25 years ago,” said CEO Peter Molloy.

In this week’s recap of substantial holder movements four substantial holders bought shares in Zenith Energy (ASX:ZEN), a Shanghai investor bought into Anson Resources (ASX:ASN) and Sirtex’s founder bought into Syrah Resources (ASX:SYR). Su...